Urine neutrophil gelatinase-associated lipocalin levels predict acute kidney injury in acute decompensated heart failure patients

References

• Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: Emergency department presentation, treatment, and disposition: Current approaches and future aims: A scientific statement from the American Heart Association. Circulation. 2010;122(19):1975–1996
   PubMed Web of Science ®Google Scholar
• Hata N, Yokoyama S, Shinada T, et al. Acute kidney injury and outcomes in acute decompensated heart failure: Evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail. 2010;12(1):32–37
   PubMed Web of Science ®Google Scholar
• Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: Results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail. 2009;11(9):847–854
   PubMed Web of Science ®Google Scholar
• Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2(1):56–62
   PubMed Web of Science ®Google Scholar
• Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 2010;36(3): 444–451
   PubMed Web of Science ®Google Scholar
• Ronco C. N-GAL: Diagnosing AKI as soon as possible. Crit Care. 2007;11(6):173
   PubMedGoogle Scholar
• Nickolas TL, O'Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148(11):810–819
   PubMed Web of Science ®Google Scholar
• Yndestad A, Landro L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 2009;30(10):1229–1236
   PubMed Web of Science ®Google Scholar
• Di Somma S, Gori CS, Salvatori E. How to manage cardiorenal syndromes in the emergency room. Contrib Nephrol. 2010;165:93–100
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31
   PubMed Web of Science ®Google Scholar
• Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19): 1527–1539
   PubMed Web of Science ®Google Scholar
• Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61–67
   PubMed Web of Science ®Google Scholar
• Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail. 2007;13(6):422–430
   PubMed Web of Science ®Google Scholar
• Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987–1996
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–216
   PubMed Web of Science ®Google Scholar
• Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 2003;63(5):1714–1724
   PubMed Web of Science ®Google Scholar
• Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17(6):1503–1520
   PubMed Web of Science ®Google Scholar
• Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004;15(7):1677–1689
   PubMed Web of Science ®Google Scholar
• Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705–2712
   PubMed Web of Science ®Google Scholar
• Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res. 2009;32(2):77–80
   PubMed Web of Science ®Google Scholar
• Koca F, Tanboga IH, Can MM, et al. Neutrophil gelatinase-associated lipocalin levels in right and left heart failure: An observational study. Anadolu Kardiyol Derg. 2011;11(6):498–503
   PubMed Web of Science ®Google Scholar
• Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010;16(1): 49–54
   PubMed Web of Science ®Google Scholar
• Alvelos M, Lourenco P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol. 2011;165:51–55
   PubMed Web of Science ®Google Scholar
• Alvelos M, Pimentel R, Pinho E, et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol. 2011;6(3):476–481
   PubMed Web of Science ®Google Scholar
• Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337–344
   PubMed Web of Science ®Google Scholar
• Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res. 2009;12(1):7–14
   PubMed Web of Science ®Google Scholar
• Shrestha K, Borowski AG, Troughton RW, Thomas JD, Klein AL, Tang WH. Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail. 2011;17(6):472–478
   PubMed Web of Science ®Google Scholar
• Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008;10(10):997–1000
   PubMed Web of Science ®Google Scholar
• Damman K, Ng Kam Chuen MJ, MacFadyen RJ, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol. 2011;57(22):2233–2241
   PubMed Web of Science ®Google Scholar
• Makris K, Markou N, Evodia E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med. 2009;47(1):79–82
   PubMed Web of Science ®Google Scholar
• Perry TE, Muehlschlegel JD, Liu KY, et al. Plasma neutrophil gelatinase-associated lipocalin and acute postoperative kidney injury in adult cardiac surgical patients. Anesth Analg. 2010;110(6):1541–1547
   PubMed Web of Science ®Google Scholar